# Revuforj® (revumenib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/revumenib

> The FDA approved Revuforj® (revumenib), sponsored by Syndax Pharmaceuticals Inc (SNDX), on October 24, 2025 for relapsed or refractory.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Revuforj® (revumenib) FDA approved?

Yes. The FDA approved Revuforj® (revumenib), sponsored by Syndax Pharmaceuticals Inc (SNDX), on October 24, 2025 for relapsed or refractory. SEC Form 8-K: "On October 24, 2025, Syndax Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved Revuforj® (revumenib) for the treatment of relapsed or refractory ("R/R") acute myeloid leukemia ("AML") with a susceptible nucleophosmin 1 ("NPM1") mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options." [Calendar and source filings](https://sec-api.dev/pdufa/revumenib)

Source: SEC Form 8-K, accession 0001193125-25-250052, https://www.sec.gov/Archives/edgar/data/1395937/000119312525250052/sndx-20251024.htm (retrieved 2026-11-12). Last confirmed 2025-11-03. Cite: https://sec-api.dev/pdufa/revumenib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Revuforj® (revumenib) |
| Codes | SNDX5613, SNDX-5613 |
| Sponsor | Syndax Pharmaceuticals Inc (SNDX) https://sec-api.dev/companies/sndx/catalysts |
| Indications | relapsed or refractory, or r/r, acute leukemia, [chronic graft-versus-host disease, or cgvhd](https://sec-api.dev/indications/chronic-graft-versus-host-disease-or-cgvhd), [relapsed or refractory](https://sec-api.dev/indications/relapsed-or-refractory), r/r acute leukemia, r/r acute myeloid leukemia, r/r mutant npm1, To treat relapsed or refractory acute leukemia, [Acute Myeloid Leukemias](https://sec-api.dev/indications/acute-myeloid-leukemias) |
| Modality | small_molecule |
| FDA designations | breakthrough, fast track, orphan, priority review |

## Timeline

### Aug 2024: FDA approval

- Status: completed, approved. Date confidence: month. Indication: chronic graft-versus-host disease, or cGVHD.
- First seen 2025-03-03, last confirmed 2026-11-02.
- SEC Form 10-Q (accession 0001193125-26-443625): "Niktimvo is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg." https://www.sec.gov/Archives/edgar/data/1395937/000119312526443625/sndx-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-332750): "Niktimvo is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg." https://www.sec.gov/Archives/edgar/data/1395937/000119312526332750/sndx-20260630.htm
- SEC Form 10-Q (accession 0001193125-25-262521): "Niktimvo is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg." https://www.sec.gov/Archives/edgar/data/1395937/000119312525262521/sndx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-101985): "Niktimvo is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg." https://www.sec.gov/Archives/edgar/data/1395937/000095017025101985/sndx-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-063518): "Niktimvo is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg." https://www.sec.gov/Archives/edgar/data/1395937/000095017025063518/sndx-20250331.htm
- SEC Form 10-K (accession 0000950170-25-030394): "Niktimvo is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg." https://www.sec.gov/Archives/edgar/data/1395937/000095017025030394/sndx-20241231.htm

### November 12, 2024: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124545): "WALTHAM, Mass., November 12, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, an oral, small molecule menin inhibitor." https://www.sec.gov/Archives/edgar/data/1395937/000095017024124545/sndx-ex99_1.htm

### November 15, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat relapsed or refractory acute leukemia.
- First seen 2024-11-18, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Revuforj | revumenib | 11/15/2024 | To treat relapsed or refractory acute leukemiaDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "NDA218944 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20241115, review_priority PRIORITY; sponsor_name SYNDAX; product REVUFORJ (REVUMENIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218944%22
- SEC Form 8-K (accession 0000950170-24-127708): "On November 15, 2024, Syndax Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory ("R/R") acute leukemia with a lysine methyltransferase 2A gene ("KMT2A") translocation in adult and pediatric patients one year and older." https://www.sec.gov/Archives/edgar/data/1395937/000095017024127708/sndx-20241115.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-127708): "WALTHAM, Mass., November 15, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) as the first and only menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older." https://www.sec.gov/Archives/edgar/data/1395937/000095017024127708/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-127708): "Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation" https://www.sec.gov/Archives/edgar/data/1395937/000095017024127708/sndx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-443625): "Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year and older." https://www.sec.gov/Archives/edgar/data/1395937/000119312526443625/sndx-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-332750): "Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year and older." https://www.sec.gov/Archives/edgar/data/1395937/000119312526332750/sndx-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-197154): "Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year and older." https://www.sec.gov/Archives/edgar/data/1395937/000119312526197154/sndx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-076536): "Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year old and older." https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm
- SEC Form 10-K (accession 0001193125-26-076536): "Revuforj is our oral, first-in-class menin inhibitor that was approved by the FDA in November 2024 for the treatment of R/R acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older." https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-262521): "Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year and older." https://www.sec.gov/Archives/edgar/data/1395937/000119312525262521/sndx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-101985): "Revuforj is our first-in-class menin inhibitor that was approved by the U.S. Food and Drug Administration, or FDA, in November 2024 for the treatment of relapsed or refractory, or R/R, acute leukemia with a lysine methyltransferase 2A gene, or KMT2A, translocation in adult and pediatric patients one year old and older." https://www.sec.gov/Archives/edgar/data/1395937/000095017025101985/sndx-20250630.htm

### December 26, 2024: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2024-11-12, last confirmed 2024-11-12.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-124545): "Positive data from the KMT2Ar AML and ALL patients in the trial supported a New Drug Application (NDA) filing for revumenib in R/R KMT2Ar acute leukemia, which is currently under review by the U.S. FDA with a PDUFA action date of December 26, 2024." https://www.sec.gov/Archives/edgar/data/1395937/000095017024124545/sndx-ex99_1.htm
- FDA novel drug approvals: "Revuforj | revumenib | 11/15/2024 | To treat relapsed or refractory acute leukemiaDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024

### Q2 2025: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-03-03, last confirmed 2025-03-03.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-030392): "The Company expects to submit a supplemental NDA (sNDA) filing for revumenib in R/R mNPM1 AML in the second quarter of 2025, followed by a potential FDA approval around year-end 2025." https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-030392): "The Company expects to file a supplemental NDA filing for revumenib in R/R mNPM1 AML in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/sndx-ex99_1.htm
- SEC Form 10-K (accession 0000950170-25-030394): "In the second quarter of 2025, we expect to submit a supplemental New Drug Application, or sNDA, for revumenib as a treatment for R/R acute myeloid leukemia, or AML, with a nucleophosmin 1 mutation, or mNPM1, based on the positive pivotal data from our AUGMENT-101 trial." https://www.sec.gov/Archives/edgar/data/1395937/000095017025030394/sndx-20241231.htm
- SEC Form 10-K (accession 0000950170-25-030394): "Based on the positive pivotal data, we expect to submit an sNDA for revumenib in R/R mNPM1 AML in the second quarter of 2025, followed by a potential FDA approval around year-end 2025." https://www.sec.gov/Archives/edgar/data/1395937/000095017025030394/sndx-20241231.htm

### Apr 2025: NDA/BLA submission

- Status: completed. Date confidence: month. Indication: R/R mutant NPM1.
- First seen 2025-05-05, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063514): "Completed the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA in April 2025, seeking Priority Review for the approval of Revuforj for the treatment of R/R mutant NPM1 (mNPM1) AML." https://www.sec.gov/Archives/edgar/data/1395937/000095017025063514/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063514): "Positive pivotal data from the AUGMENT-101 trial in this population with revumenib as a monotherapy were recently reported and the Company submitted a supplemental NDA for revumenib in R/R mNPM1 AML in April 2025." https://www.sec.gov/Archives/edgar/data/1395937/000095017025063514/sndx-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-076536): "In April 2025, the Company submitted an sNDA for Revuforj with the FDA." https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm
- SEC Form 10-Q (accession 0000950170-25-101985): "In April 2025, we completed the submission of a supplemental New Drug Application, or sNDA, for revumenib as a treatment for R/R acute myeloid leukemia, or AML, with a nucleophosmin 1 mutation, or mNPM1, based on the positive pivotal data from our AUGMENT-101 trial." https://www.sec.gov/Archives/edgar/data/1395937/000095017025101985/sndx-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-063518): "In April 2025, we completed the submission of a supplemental New Drug Application, or sNDA, for revumenib as a treatment for R/R acute myeloid leukemia, or AML, with a nucleophosmin 1 mutation, or mNPM1, based on the positive pivotal data from our AUGMENT-101 trial." https://www.sec.gov/Archives/edgar/data/1395937/000095017025063518/sndx-20250331.htm

### June 30, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2025-08-04, last confirmed 2025-08-04.
- SEC Form 10-Q (accession 0000950170-25-101985): "In the three months ended June 30, 2025 the Company the submitted an supplemental New Drug Application (sNDA) to the U.S. FDA for a second indication for Revuforj." https://www.sec.gov/Archives/edgar/data/1395937/000095017025101985/sndx-20250630.htm

### October 24, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: relapsed or refractory.
- First seen 2025-10-24, last confirmed 2025-11-03.
- SEC Form 8-K (accession 0001193125-25-250052): "On October 24, 2025, Syndax Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved Revuforj® (revumenib) for the treatment of relapsed or refractory ("R/R") acute myeloid leukemia ("AML") with a susceptible nucleophosmin 1 ("NPM1") mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options." https://www.sec.gov/Archives/edgar/data/1395937/000119312525250052/sndx-20251024.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-250052): "NEW YORK, October 24, 2025 (GLOBE NEWSWIRE) - Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved Revuforj® (revumenib) for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options." https://www.sec.gov/Archives/edgar/data/1395937/000119312525250052/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-262509): "Received U.S. FDA approval for Revuforj on October 24, 2025, for the treatment of R/R acute myeloid leukemia (AML) with a susceptible NPM1 mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options." https://www.sec.gov/Archives/edgar/data/1395937/000119312525262509/sndx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-25-262521): "On October 24, 2025, the Company announced FDA approval of Revuforj® (revumenib) for the treatment of relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options." https://www.sec.gov/Archives/edgar/data/1395937/000119312525262521/sndx-20250930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-250052): "Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia" https://www.sec.gov/Archives/edgar/data/1395937/000119312525250052/sndx-ex99_1.htm

### October 24, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218944 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20251024, review_priority PRIORITY; sponsor_name SYNDAX; product REVUFORJ (REVUMENIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218944%22

### October 25, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-08-04, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101974): "PDUFA target action date of October 25, 2025 IC, intensive chemotherapy" https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_2.htm
- SEC Form 10-Q (accession 0000950170-25-101985): "In June 2025, the FDA granted Priority Review to our sNDA and assigned a Prescription Drug User Fee Act, or PDUFA, target action date of October 25, 2025." https://www.sec.gov/Archives/edgar/data/1395937/000095017025101985/sndx-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-105051): "In June 2025, they announced that the FDA accepted and granted Priority Review for their supplemental NDA, or sNDA, for revumenib in relapsed or refractory NPM1-mutant AML, is reviewing the sNDA under the Real-Time Oncology Review program and assigned the sNDA a PDUFA target action date of October 25, 2025." https://www.sec.gov/Archives/edgar/data/1422143/000095017025105051/kura-20250630.htm
- SEC Form 8-K (accession 0001193125-25-250052): "On October 24, 2025, Syndax Pharmaceuticals, Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has approved Revuforj® (revumenib) for the treatment of relapsed or refractory ("R/R") acute myeloid leukemia ("AML") with a susceptible nucleophosmin 1 ("NPM1") mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options." https://www.sec.gov/Archives/edgar/data/1395937/000119312525250052/sndx-20251024.htm

### Nov 2025: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2026-01-12, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-076522): "Initiated REVEAL-ND, a Phase 3, randomized, double-blind, placebo-controlled trial of revumenib in combination with intensive chemotherapy in newly diagnosed patients with NPM1m AML in November 2025." https://www.sec.gov/Archives/edgar/data/1395937/000119312526076522/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-010486): "Initiated REVEAL-ND, a Phase 3, randomized, double-blind, placebo-controlled trial of revumenib in combination with intensive chemotherapy in newly diagnosed patients with NPM1m AML in November 2025." https://www.sec.gov/Archives/edgar/data/1395937/000119312526010486/sndx-ex99_1.htm
- SEC Form 10-K (accession 0001193125-26-076536): "REVEAL-ND: In November 2025, we initiated a pivotal, Phase 3, randomized, double-blind, placebo-controlled trial of revumenib in combination with intensive chemotherapy in newly diagnosed NPM1m AML patients." https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm

### 2026: trial start

- Status: scheduled. Date confidence: year. Stage: 2.
- First seen 2026-01-12, last confirmed 2026-01-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-010486): "Initiate RAVEN, a Phase 2 collaborative trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed KMT2Ar patients who would be considered eligible, or fit, for intensive chemotherapy in 2026." https://www.sec.gov/Archives/edgar/data/1395937/000119312526010486/sndx-ex99_1.htm

### 2H 2026: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2025-08-04, last confirmed 2025-08-04.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101974): "Trial initiation anticipated in 4Q25 Dual primary endpoints: MRD negative CR & EFS to support potential for accelerated and full approval, respectively Topline MAXPIRe data anticipated in 2H26 Enrollment underway in EVOLVE-2 Dual primary endpoints: CR and OS in mNPM1 pts. to support potential for accelerated and full approval, respectively" https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_2.htm

### 2H 2027: interim data readout

- Status: scheduled. Date confidence: half. Stage: 1/2.
- First seen 2026-08-04, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-443613): "The development of SNDX-62122 will be informed by a Phase 1/2 proof-of-principle trial of revumenib in MF that is expected to initiate in the fourth quarter of 2026 with initial clinical data expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-332736): "The development of SNDX-62122 will be informed by a Phase 1/2 proof-of-principle trial of revumenib in MF that is expected to initiate in the fourth quarter of 2026 with initial clinical data expected in the second half of 2027." https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/sndx-ex99_1.htm

### June 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Acute Myeloid Leukemias.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07211958 (Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Syndax Pharmaceuticals." https://clinicaltrials.gov/study/NCT07211958

### Jun to Sep 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Acute Myeloid Leukemias.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07211958 (Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Syndax Pharmaceuticals." https://clinicaltrials.gov/study/NCT07211958

## Same indication

- [NIKTIMVO (axatilimab)](https://sec-api.dev/pdufa/axatilimab) (INCY)
- [TEPKINLY (epcoritamab)](https://sec-api.dev/pdufa/epcoritamab) (GMAB)
- [GTB-3650](https://sec-api.dev/pdufa/gtb-3650) (GTBP)
- [KOMZIFTI (ziftomenib)](https://sec-api.dev/pdufa/ziftomenib) (KURA)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/revumenib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Revuforj® (revumenib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/revumenib

```bibtex
@misc{secapidev_pdufa_revumenib_20261116,
  title        = {Revuforj® (revumenib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/revumenib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_revumenib_20261116","title":"Revuforj® (revumenib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/revumenib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
